Magnetic resonance imaging (MRI) has transformed prostate cancer diagnosis by enhancing lesion detection, guiding targeted biopsies, and reducing unnecessary procedures [1–3]. Despite these advancements, MRI performance in tumor (T) staging remains variable, particularly in distinguishing organ-confined (T2) from locally advanced (T3a) disease. Accurate radiological assessment of extraprostatic extension poses persistent challenges [4], exposing patients to the risk of both undertreatment and ov…